Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX

J Gastrointest Cancer. 2014 Dec:45 Suppl 1:278-81. doi: 10.1007/s12029-014-9662-3.

Authors

Zachary Reese¹, Shiven Patel, David D Stenehjem, Ignacio Garrido-Laguna

Affiliation

¹ Department of Internal Medicine (Division of Oncology) and Center for Investigational Therapeutics, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Suite 2100, Salt Lake City, UT, 84112, USA.

PMID: 25367745
DOI: 10.1007/s12029-014-9662-3

No abstract available

MeSH terms

Albumins / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Drug Resistance, Neoplasm
Gastrointestinal Neoplasms / drug therapy*
Gemcitabine
Humans
Male
Middle Aged
Paclitaxel / administration & dosage

Substances

130-nm albumin-bound paclitaxel
Albumins
Deoxycytidine
Paclitaxel
Gemcitabine